These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 10731049)

  • 101. Effect of Cremophor EL on the pharmacokinetics, antitumor activity and toxicity of doxorubicin in mice.
    Badary OA; Al-Shabanah OA; Al-Gharably NM; Elmazar MM
    Anticancer Drugs; 1998 Oct; 9(9):809-15. PubMed ID: 9840728
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Differential modulation of cisplatin accumulation in leukocytes and tumor cell lines by the paclitaxel vehicle Cremophor EL.
    de Vos AI; Nooter K; Verweij J; Loos WJ; Brouwer E; de Bruijn P; Ruijgrok EJ; van der Burg ME; Stoter G; Sparreboom A
    Ann Oncol; 1997 Nov; 8(11):1145-50. PubMed ID: 9426335
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Modulation of cisplatin pharmacodynamics by Cremophor EL: experimental and clinical studies.
    Gelderblom H; Loos WJ; Verweij J; van der Burg ME; de Jonge MJ; Brouwer E; Nooter K; Stoter G; Sparreboom A
    Eur J Cancer; 2002 Jan; 38(1):205-13. PubMed ID: 11750851
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Evaluation of cisplatin combined with ondansetron in Ehrlich ascites carcinoma in vitro and in vivo.
    Badary OA; Sharaby SM; Kenawy SA; El-Denshary EE; Hamada FM
    Tumori; 2000; 86(2):153-6. PubMed ID: 10855854
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Drug interactions of paclitaxel and docetaxel and their relevance for the design of combination therapy.
    Vigano L; Locatelli A; Grasselli G; Gianni L
    Invest New Drugs; 2001 May; 19(2):179-96. PubMed ID: 11392452
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Pharmacological effects of formulation vehicles : implications for cancer chemotherapy.
    ten Tije AJ; Verweij J; Loos WJ; Sparreboom A
    Clin Pharmacokinet; 2003; 42(7):665-85. PubMed ID: 12844327
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation.
    Gelderblom H; Verweij J; Nooter K; Sparreboom A
    Eur J Cancer; 2001 Sep; 37(13):1590-8. PubMed ID: 11527683
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Pharmacology and toxicology of Cremophor EL diluent.
    Dorr RT
    Ann Pharmacother; 1994 May; 28(5 Suppl):S11-4. PubMed ID: 7915152
    [No Abstract]   [Full Text] [Related]  

  • 109. Role of formulation vehicles in taxane pharmacology.
    van Zuylen L; Verweij J; Sparreboom A
    Invest New Drugs; 2001 May; 19(2):125-41. PubMed ID: 11392447
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Differential alteration of cisplatin cytotoxicity and myelotoxicity by the paclitaxel vehicle cremophor EL.
    Badary OA; Abdel-Naim AB; Khalifa AE; Hamada FM
    Naunyn Schmiedebergs Arch Pharmacol; 2000 Mar; 361(3):339-44. PubMed ID: 10731049
    [TBL] [Abstract][Full Text] [Related]  

  • 111.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 6.